CLEOPATRA: What the Breast Cancer Trial Found

Two antibodies, one receptor

HER2 is a receptor on the cell surface. When the gene making it is amplified, the cell carries far too many, and the growth signal never stops.

Trastuzumab, approved in 1998, was the first antibody aimed at it. But most advanced disease eventually progressed anyway.

Pertuzumab attacks the same receptor differently. NCI's clinical summary explains that it binds a distinct part of the HER2 extracellular domain — a different epitope from trastuzumab — and prevents HER2 from pairing up with other HER receptors, most notably HER3. That pairing, called dimerization, is how the growth signal gets switched on.

Two antibodies on one receptor, blocking two things. CLEOPATRA tested whether adding the second was worth it.

How CLEOPATRA was built

CLEOPATRA was a phase 3 trial. Its ClinicalTrials.gov record, NCT00567190, lists 808 participants, randomized, with triple masking covering participants, investigators, and outcome assessors.

Everyone had HER2-positive metastatic breast cancer and had not yet received chemotherapy or anti-HER2 treatment for their metastatic disease.

They received trastuzumab plus docetaxel, with either pertuzumab or a matching placebo added. Treatment continued until the cancer progressed or side effects became unmanageable.

The primary endpoint was independently assessed progression-free survival. Overall survival was a secondary endpoint. That ordering matters when reading what follows.

The first result, in 2012

Median progression-free survival was 12.4 months in the control group and 18.5 months in the pertuzumab group.

The hazard ratio for progression or death was 0.62, with a 95% confidence interval of 0.51 to 0.75 and a p-value below 0.001.

The interim look at overall survival showed a strong trend in favor of pertuzumab but was not yet conclusive.

The survival result, in 2015

The final prespecified overall survival analysis came after a median follow-up of 50 months.

Median overall survival was 56.5 months with pertuzumab, against 40.8 months with placebo. That is a difference of 15.7 months. The hazard ratio for death was 0.68, with a 95% confidence interval of 0.56 to 0.84 and a p-value below 0.001.

Some placebo patients had crossed over to pertuzumab after the interim analysis. The reported figure was not adjusted for that, which makes it conservative rather than inflated. Sensitivity analyses adjusting for crossover were consistent with it.

Investigator-assessed progression-free survival improved by 6.3 months. Median duration of response was extended by 7.7 months.

NCI's clinical summary adds a longer view: eight-year landmark overall survival was 37% with pertuzumab and 23% with placebo.

A median survival beyond four and a half years in metastatic breast cancer was not a familiar number in 2015. It is the reason this trial is cited as often as it is.

What it costs

The safety profile was broadly similar between the two groups, and NCI notes no increase in cardiac toxic effects with the pertuzumab combination. That was the outcome people were watching for, given trastuzumab's history with the heart.

Two things were worse with pertuzumab. Grade 3 or higher febrile neutropenia — a dangerous fever with very low white cells — was more common, as was grade 3 or higher diarrhea.

Most adverse events in both groups occurred while docetaxel was being given. Docetaxel is a taxane chemotherapy, and it brings hair loss, low blood counts, and nerve damage in the hands and feet. Long-term cardiac safety was maintained through follow-up.

When to get checked

For anyone on this combination, one symptom overrides everything else. A fever of 38 degrees Celsius, or 100.4 Fahrenheit, during a chemotherapy cycle is an emergency. Febrile neutropenia is treatable, and treated early it is usually survivable, but the window is hours rather than days.

Diarrhea should be reported before it becomes dehydrating, not after.

Heart function is monitored on a schedule with any anti-HER2 treatment. Between checks, new breathlessness on mild exertion, waking short of breath, or swelling in the ankles should be reported.

For breast cancer itself, NCI is clear that early disease often has no symptoms, which is what makes screening the main route to early detection. When changes do appear, NCI says to check with a doctor about a lump in or near the breast or under the arm, a thick or firm area, a change in breast size or shape, and nipple changes or discharge.

A new lump that persists through a menstrual cycle, or any new lump after menopause, is worth an appointment. Our overview of breast cancer covers what happens next.

The population behind the numbers

About 321,910 new female breast cancer diagnoses and 42,140 deaths are projected in the United States for 2026 — an American Cancer Society estimate that SEER publishes. The median age at diagnosis is 64.

Six percent is diagnosed after spread to distant sites, and five-year relative survival in that group is 33.8%. Across all stages it is 91.9% for women diagnosed from 2016 through 2022.

CLEOPATRA enrolled entirely from that 6%, and only the HER2-positive part of it. Registry averages across all subtypes describe a population and not the people in this trial. Our page on metastatic cancer covers what distant spread means.

What this trial cannot tell you

Overall survival was a secondary endpoint. The protocol's primary endpoint was independently assessed progression-free survival. That does not make the survival result invalid — it was prespecified and alpha-controlled — but it is not what the trial was powered around.

The results apply only to HER2-positive disease, and only to people fit enough for docetaxel. Anyone who cannot tolerate a taxane is outside this evidence.

The trial also tested one specific combination as first treatment for metastatic disease. It says nothing about later lines, and nothing about the antibody-drug conjugates that have since changed HER2-positive care.

And a median is a midpoint, not a prediction. Half the pertuzumab group lived less than 56.5 months.

Sources

• Swain SM et al., N Engl J Med 2015, CLEOPATRA final survival (NCBI E-utilities)
• Baselga J et al., N Engl J Med 2012, CLEOPATRA primary analysis (NCBI E-utilities)
• ClinicalTrials.gov record for NCT00567190 (CLEOPATRA)
• NCI PDQ: Breast Cancer Treatment (Health Professional Version)
• NCI: Breast Cancer Signs and Symptoms
• NCI SEER Stat Facts: Female Breast Cancer

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

See an error, old source, or unclear wording? Tell us.